Connect Biopharma Holdings Limited · NASDAQ:CNTB

Connect Biopharma — Technical Presentation (June 2024)

9 slides from Connect Biopharma's technical presentation, June 2024

  1. Slide 1: Positive 52-Week Maintenance Data Observed with Rademikibart in Moderate-to-Severe Atopic Dermatitis

    Positive 52-Week Maintenance Data Observed with Rademikibart in Patients with 1 Moderate-to-Severe Atopic Dermatitis (SEASIDE CHINA) Jianzhong Zhang,1 Jonathan I. Silverberg,2 Jiawang Guo,3 Jili Yun,3 Wuban Pan,3 Zheng Wei,4 Raúl Collazo4 1Peking University People’s Hospital, Department of Dermatolo

  2. Slide 2: SEASIDE CHINA: Study Design, Inclusion Criteria, Endpoints, and Treatment Completion Rates

    SEASIDE CHINA: 2 Study Design, Inclusion Criteria, Endpoints, and Treatment Completion Rates STAGE 1 STAGE 2 YES Rademikibart 300 mg Q2W Rademikibart (R 1:1) N=113 600 mg LD on Day 1 + 300 mg Q2W R 2:1 N=219 EASI-50? Rademikibart 300 mg Q4W N=330 Follow-up N=112 Placebo N=111 NO Rademikibart 300 mg

  3. Slide 3: Maintenance of IGA 0/1 and EASI-75 Responses Sustained Through Week 52

    Maintenance of IGA 0/1 and EASI-75 Responses Observed at 3 Week 16 were Sustained Through Week 52 vIGA 0/1 and ≥2-Point Reduction EASI-75 (Percentage of Week 16 vIGA 0/1 responders to (Percentage of Week 16 EASI-75 responders to rademikibart maintaining response)* rademikibart maintaining response)

  4. Slide 4: PP-NRS ≥4-Point Responses Highly Maintained from Week 16 Through Week 52

    PP-NRS ≥4-Point Responses were also Highly Maintained from 4 Week 16 Through Week 52 PP-NRS ≥4-Point Reduction (Percentage of Week 16 PP-NRS responders to rademikibart maintaining response)* 100% 95.2% 90% PP-NRS Responders (%) 80% 81.6% 70% 60% 50% 40% 30% 20% Rademikibart Q2W (n=38) 10% Rademikiba

  5. Slide 5: Among EASI-50 Responders, Continued Improvement of IGA 0/1 Response

    Among EASI-50 Responders, Continued Improvement of IGA 0/1 5 Response was Observed with Rademikibart (through Week 52) vIGA 0/1 and ≥2-point reduction EASI-50 Response at Week 16 Overall Population Week 16 EASI-50 Responders† 41.5%*** 80% Patients with vIGA 0/1 Response (%) 100% Patients with EASI-5

  6. Slide 6: Continued Improvement of EASI-75 and PP-NRS with Rademikibart Treatment

    Continued Improvement of EASI-75 and PP-NRS were Observed 6 with Rademikibart Treatment (Baseline through Week 52) EASI-75 PP-NRS ≥4-Point Reduction Overall Population Week 16 EASI-50 Responders† Overall Population Week 16 EASI-50 Responders† Patients with PP-NRS ≥4-Point Reduction (%) 100% 80% 84.8

  7. Slide 7: Continued Improvement of EASI and PP-NRS Scores with Rademikibart

    Continued Improvement of EASI and PP-NRS Scores were 7 Observed with Rademikibart (Baseline through Week 52) EASI Score PP-NRS Score Overall Population Week 16 EASI-50 Responders Overall Population Week 16 EASI-50 Responders 0% 0% -10% -10% LSM % Change from Baseline LSM % Change from Baseline -20%

  8. Slide 8: No new safety signals compared with previous rademikibart trials

    No new safety signals compared with previous rademikibart 8 trials,1,2 including no treatment-related serious events Stage 1 (Weeks 0–16) Stage 2 (Weeks 16–60) Rademikibart Q2W, Rademikibart Q2W Rademikibart Q4W Rademikibart Q2W Placebo (W16 non- (W16 responders)* (W16 responders)* N=219 N=111 respo

  9. Slide 9: Conclusion: SEASIDE CHINA supports long-term monthly dosing of rademikibart

    Conclusion: 9 SEASIDE CHINA supports long-term monthly dosing of rademikibart • Skin clearance (IGA0/1, EASI) and pruritus (PP-NRS) improvements at Week 16 in SEASIDE CHINA Efficacy continuously (dosed Q2W) were compatible with WW001 global Phase 2 trial results (dosed Q2W and Q4W).1 improved throug

Connect Biopharma Holdings — Technical Presentation (June 2024) on 6ix